메뉴 바로가기
주메뉴 바로가기
컨텐츠 바로가기

Products

PRODUCTS

Biologics

Project code name

PAK255

Competitiveness
  • The world's first treatment for tick-borne severe fever with thrombocytopenia syndrome
  • Treatment for infectious diseases caused by all types of SFTSV found in Korea, China and Japan
  • Promotion of joint development between the two companies to commercialize them as pharmaceuticals
  • Adoption of a national project by the NOHW(2021.04~2022.12.31)
  • Research service performance of the Korea Disease Control and Prevention Agency, National Institute of Health (June 2023 - April 2025)
Major Functions
and Characteristics
  • Severe fever with thrombocytopenia syndrome (SFTS) is caused by ticks infected with the SFTS virus. It is a severe infectious disease mediated by infection.
  • These mites are mainly distributed in China, Korea, Japan, Russia and Australia
  • Infection with SFTS virus causes fever, gastrointestinal symptoms, neutropenia and thrombocytopenia. If infected persons show clinical symptoms and do not recover, they will progress to multiple organ dysfunction and eventual death.
  • Anti-SFTSV antibody under development is targeting the glycoproteins of outer membrane of the virus that causes thrombocytopenia syndrome(SFTSV). This specific neutralizing antibody against the virus can be used as an effective antibody therapeutics.
  • The effectiveness of this antibody treatment has been verified through animal model studies.
  • Optimum dose and dosage frequency will be determined through the oncoming clinical research
  • Development stage: Production cell line and process technology completed (2020.08)